Similar articles

• Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.

  Centers for Disease Control and Prevention (CDC). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2002 Nov 8;51(44):998-9. MMWR Morb Mortal Wkly Rep. 2002. PMID: 12455909
• From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.

  [No authors listed] [No authors listed] JAMA. 2001 Sep 26;286(12):1445-6. JAMA. 2001. PMID: 11596606 No abstract available.
• From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.

  [No authors listed] [No authors listed] JAMA. 2001 May 23-30;285(20):2572-3. JAMA. 2001. PMID: 11396466 No abstract available.
• Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?

  Jasmer RM, Daley CL. Jasmer RM, et al. Am J Respir Crit Care Med. 2003 Mar 15;167(6):809-10. doi: 10.1164/rccm.2301002. Am J Respir Crit Care Med. 2003. PMID: 12623855 Review. No abstract available.
• Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.

  Stout JE. Stout JE. Expert Opin Drug Saf. 2004 May;3(3):187-98. doi: 10.1517/eods.3.3.187.31073. Expert Opin Drug Saf. 2004. PMID: 15155147 Review.